Nontuberculous Mycobacteria Market is predicted to reach USD 11.114 billion at a CAGR of 2.50% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Nontuberculous Mycobacteria Market”.

The Nontuberculous Mycobacteria market is estimated to register a CAGR of 2.50% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global Nontuberculous Mycobacteria market - Insmed, Paratek Pharmaceuticals Inc, RedHill Biopharma Ltd, Janssen, Novartis AG, RevImmune, and Nobelpharma Co Ltd.

Market Highlights

The global Nontuberculous Mycobacteria market is accounted to register a CAGR of 2.50% during the forecast period and is estimated to reach USD 11.114 billion by 2032.

The rising incidence of nontuberculous mycobacterial lung illness, particularly among the older population worldwide, is responsible for the market's expansion. Additionally, the growing elderly population worldwide is anticipated to support market expansion. As of 2020, 723,484,054 people were older over 64, according to World Bank statistics. Furthermore, it is anticipated that the rising prevalence of several lung-related conditions among people will accelerate market expansion. In addition, rising health expenditures, government measures to provide effective healthcare facilities, and rising public health awareness are predicted to fuel market expansion.

Access full report @ https://www.marketresearchfuture.com/reports/nontuberculous-mycobacteria-market-16170

Segment Analysis

The global Nontuberculous Mycobacteria market has been segmented into class of drugs.

Based on class of drugs, the global Nontuberculous Mycobacteria market has been segmented into Oral Antibiotics, IV Antibiotics, Anti Nausea, and Nebulized Antibiotics. The oral antibiotics segment was expected to hold the largest market share in 2022 Due to its efficaciousness in treating mycobacterial infections. The most successful drug now on the market for treating NTM infections is azithromycin, an oral macrolide antibiotic that has shown promise in treating a range of NTM strains. Oral antibiotics are often prescribed in combination with other drugs to treat NTM infections, according to clinical recommendations. Thus, the growth of the oral antibiotic category for nontuberculous NTM infections will be accelerated by these factors.

Regional Analysis

The global Nontuberculous Mycobacteria market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Nontuberculous Mycobacteria market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Nontuberculous Mycobacteria market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Nontuberculous Mycobacteria market comprises of Middle East, Africa, and Latin America.

The largest market share for Nontuberculous Mycobacteria was maintained by the North American regional sector due to the prevalence of nontuberculous mycobacterium infections. The market is expected to grow as a result of the presence of big pharmaceutical companies, increased research activities to develop new medications, and rising healthcare expenses.

Moreover, the Europe market has been persistently growing over the forecast period. With more people choosing quick-fix, high-impact treatments, this market has a wealth of opportunities. Market increase will be fueled by spending by health departments.  The substance, which is extremely helpful to the populace, has been brilliantly marketed by the European Medicines Agency.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. A major factor is the increasing incidence of NTM infections in Asia Pacific, especially in those with weakened immune systems or underlying respiratory diseases. With cutting-edge diagnostic capabilities and a thriving pharmaceutical industry, this region boasts a sophisticated healthcare infrastructure.

Furthermore, the rest of the world's Nontuberculous Mycobacteria market is divided into the Middle East, Africa, and Latin America. The market for nontuberculous mycobacterium is expanding significantly throughout the rest of the world as a result of rising rates of chronic disease worldwide. The increase in malignant illnesses that compromise immunity is another factor contributing to the expansion.

Key Findings of the Study

• The global Nontuberculous Mycobacteria market is expected to reach USD 11.114 billion by 2032, at a CAGR of 2.50% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. The rising prevalence of NTM infections in Asia Pacific, particularly in those with compromised immune systems or underlying respiratory conditions, is a significant contributing cause.


• Based on class of drugs, the oral antibiotics segment was attributed to holding the largest market in 2022, with an approximate market share of 55%.


• Insmed, Paratek Pharmaceuticals Inc, RedHill Biopharma Ltd, Janssen, Novartis AG, RevImmune, and Nobelpharma Co Ltd.